Global Biologics Contract Manufacturing Market Overview

• The Global Biologics Contract Manufacturing Market Size was worth around USD 28.94 Billion in 2023 and is Predicted to Grow to around USD 76.89 Billion by 2033 with a compound annual growth rate (CAGR) of 10.26% Between 2023 and 2033.
• The market growth is rising due to driven by the rise in the need for biologics, and advanced drugs have also created a growing demand for CMOs and CDMOs.
• The Biologics Contract Manufacturing market refers to the industry that involves contracting out the manufacture of biologic drugs—vaccines, antibodies, and cell therapies—to third-party specialist firms.

Major vendors in the Global Biologics Contract Manufacturing Market

Wuxi Biologics, FUJIFILM Diosynth Biotechnologies., Boehringer Ingelheim International GmbH, Lonza, Samsung Biologics., AbbVie Inc., Catalent, Bioreliance (Merck KGaA), Thermo Fisher Scientific Inc., Eurofins Scientific, and others.

Market Segment

This study forecasts revenue at the global, regional, and country levels from 2023 to 2033. Decision Advisors has segmented the Biologics Contract Manufacturing market based on the below-mentioned segments:

Global Biologics Contract Manufacturing Market, By Product

• MABs
• Recombinant Protein

Global Biologics Contract Manufacturing Market, By Indication

• Oncology
• CVDs

Global Biologics Contract Manufacturing Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa